Breaking News, Financial News

Financial Report: Celgene 4Q09

Record revenues for Celgene in 2009

Celgene 4Q09

4Q Revenues: $761 million (+21%)

4Q Earnings: $254 million (loss of $154 million in 4Q08)

FY Revenues: $2.7 billion (+19%)

FY Earnings: $776 million (loss of $1.5 billion in FY08)

Comments: Revlimid sales were up 29% to $1.7 billion in FY09, and up 35% to $497 million in 4Q09. Losses in FY08 were largely attributed to the acquisition of Pharmion Corp. in-process R&D write-downs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters